Additionally, Ubenimex is a CD13 inhibitor that was able to show promising effects from in vitro studies to clinical trials; in the Phase I clinical trials it was observed to prolong survival of AML patients but to also promote graft versus leukaemia effects in patients post-transplant [78]. The gene discussed is ANPEP; the disease is acute myeloid leukemia.